Is Aurinia Pharmaceuticals a Buy?

There's good news and bad news for Aurinia Pharmaceuticals (NASDAQ: AUPH) shareholders. Let's start with the good news. The company has had a fantastic 2017, with its stock price soaring more than 120% year to date with less than two weeks remaining in the year.

Now for the bad news. All of those gains -- and a lot more -- came during the first few months of the year. Since late March, Aurinia has lost nearly half of its market cap. This big pullback resulted primarily from a stock offering that diluted the value of existing shares. But with a new year just around the corner, is Aurinia Pharmaceuticals a buy now?

Image source: Getty Images.

Source: Fool.com